Kai-Qin Jiang

Sintilimab plus R-CHOP versus DA-EPOCH-R as first-line therapy for primary mediastinal large B-cell lymphoma: a real-world comparative cohort study

Primary mediastinal large B-cell lymphoma (PMBCL) is a highly curable lymphoma in which first-line therapy must balance durable disease control with acute and late treatment toxicity. We retrospectively analyzed 98 patients with newly diagnosed PMBCL who received sintilimab plus R-CHOP (group 1, n = 42) or D...